These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 26059652)

  • 1. Postoperative Morbidity and Mortality Rates are Not Increased for Patients with Gastric and Gastroesophageal Cancer Who Undergo Preoperative Chemoradiation Therapy.
    Badgwell B; Ajani J; Blum M; Ho L; Fournier K; Chiang YJ; Matamoros A; Das P; Mansfield P
    Ann Surg Oncol; 2016 Jan; 23(1):156-62. PubMed ID: 26059652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is preoperative chemotherapy followed by surgery the appropriate treatment for signet ring cell containing adenocarcinomas of the esophagogastric junction and stomach?
    Heger U; Blank S; Wiecha C; Langer R; Weichert W; Lordick F; Bruckner T; Dobritz M; Burian M; Springfeld C; Grenacher L; Siewert JR; Büchler M; Ott K
    Ann Surg Oncol; 2014 May; 21(5):1739-48. PubMed ID: 24419755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Survival in Patients with Gastroesophageal Junction Cancer Treated with Preoperative Therapy: Do Thoracic and Abdominal Approaches Differ?
    Kneuertz PJ; Hofstetter WL; Chiang YJ; Das P; Blum M; Elimova E; Mansfield P; Ajani J; Badgwell B
    Ann Surg Oncol; 2016 Feb; 23(2):626-32. PubMed ID: 26564243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequency of Resection After Preoperative Chemotherapy or Chemoradiotherapy for Gastric Adenocarcinoma.
    Badgwell B; Blum M; Elimova E; Estrella J; Chiang YJ; Das P; Mansfield P; Ajani J
    Ann Surg Oncol; 2016 Jun; 23(6):1948-55. PubMed ID: 26868957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-morbidities Rather than Age Impact Outcomes in Patients Receiving Preoperative Therapy for Gastroesophageal Adenocarcinoma.
    Charalampakis N; Xiao L; Lin Q; Elimova E; Shimodaira Y; Harada K; Rogers JE; Mares J; Amlashi FG; Minsky BD; Das P; Hofstetter WL; Matamoros A; Sagebiel TL; Blum-Murphy MA; Lee JH; Weston B; Bhutani MS; Mansfield PF; Estrella JS; Badgwell BD; Ajani JA
    Ann Surg Oncol; 2017 Aug; 24(8):2291-2301. PubMed ID: 27770339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of repeat staging laparoscopy in locoregionally advanced gastric or gastroesophageal cancer after neoadjuvant therapy.
    Cardona K; Zhou Q; Gönen M; Shah MA; Strong VE; Brennan MF; Coit DG
    Ann Surg Oncol; 2013 Feb; 20(2):548-54. PubMed ID: 22941159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of induction chemotherapy and preoperative chemoradiotherapy on operative morbidity and mortality in patients with locoregional adenocarcinoma of the stomach or gastroesophageal junction.
    Fujitani K; Ajani JA; Crane CH; Feig BW; Pisters PW; Janjan N; Walsh GL; Swisher SG; Vaporciyan AA; Rice D; Welch A; Baker J; Faust J; Mansfield PF
    Ann Surg Oncol; 2007 Jul; 14(7):2010-7. PubMed ID: 17342569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of postoperative TNM stages after neoadjuvant therapy on prognosis of adenocarcinoma of the gastro-oesophageal junction tumours.
    Thomaschewski M; Hummel R; Petrova E; Knief J; Wellner UF; Keck T; Bausch D
    World J Gastroenterol; 2018 Apr; 24(13):1429-1439. PubMed ID: 29632424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of Skeletal Muscle Mass During Neoadjuvant Chemoradiotherapy Predicts Postoperative Mortality in Esophageal Cancer Surgery.
    Reisinger KW; Bosmans JW; Uittenbogaart M; Alsoumali A; Poeze M; Sosef MN; Derikx JP
    Ann Surg Oncol; 2015 Dec; 22(13):4445-52. PubMed ID: 25893413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perioperative chemotherapy vs. neoadjuvant chemoradiation in gastroesophageal junction adenocarcinoma : A population-based evaluation of the Munich Cancer Registry.
    Münch S; Habermehl D; Agha A; Belka C; Combs SE; Eckel R; Friess H; Gerbes A; Nüssler NC; Schepp W; Schmid RM; Schmitt W; Schubert-Fritschle G; Weber B; Werner J; Engel J
    Strahlenther Onkol; 2018 Feb; 194(2):125-135. PubMed ID: 29071366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postoperative intraperitoneal 5-fluoro-2'-deoxyuridine added to chemoradiation in patients curatively resected (R0) for locally advanced gastric and gastroesophageal junction adenocarcinoma.
    Cohen DJ; Newman E; Iqbal S; Chang RY; Potmesil M; Ryan T; Donahue B; Chandra A; Liu M; Utate M; Hiotis S; Pachter LH; Hochster H; Muggia F
    Ann Surg Oncol; 2012 Feb; 19(2):478-85. PubMed ID: 21769462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant chemoradiation with 5-fluorouracil/leucovorin versus S-1 in gastric cancer patients following D2 lymph node dissection surgery: a feasibility study.
    Lee SJ; Sohn TS; Lee J; Park SH; Park JO; Lim DH; Park YS; Lim HY; Choi MG; Lee JH; Bae JM; Kim S; Kang WK
    Anticancer Res; 2014 Nov; 34(11):6585-91. PubMed ID: 25368262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of preoperative radiochemotherapy on survival in advanced esophagogastric junction signet ring cell adenocarcinoma.
    Bekkar S; Gronnier C; Messager M; Robb WB; Piessen G; Mariette C;
    Ann Thorac Surg; 2014 Jan; 97(1):303-10. PubMed ID: 24200394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant Therapy Improves Outcomes in Locally Advanced Signet-Ring-Cell Containing Esophagogastric Adenocarcinomas.
    Heger U; Sisic L; Nienhüser H; Blank S; Hinz U; Haag GM; Ott K; Ulrich A; Büchler MW; Schmidt T
    Ann Surg Oncol; 2018 Aug; 25(8):2418-2427. PubMed ID: 29855828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative chemotherapy with cisplatin and docetaxel followed by surgery and clip-oriented postoperative chemoradiation in patients with localized gastric or gastroesophageal junction adenocarcinoma: results from a phase II feasibility study.
    Spizzo G; Öfner D; de Vries A; Lukas P; Steger G; Pluschnig U; Zacherl J; Widder J; Zabernigg A; Gastl G; Mühlmann G
    Ann Surg Oncol; 2011 Mar; 18(3):677-83. PubMed ID: 21063792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of neoadjuvant therapy for gastroesophageal adenocarcinoma on postoperative morbidity and mortality.
    Fuentes E; Ahmad R; Hong TS; Clark JW; Kwak EL; Rattner DW; Mullen JT
    J Surg Oncol; 2016 Apr; 113(5):560-4. PubMed ID: 26792144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conditional survival in patients with esophageal or gastroesophageal junction cancer after receiving various treatment modalities.
    Deng W; Yang Z; Dong X; Yu R; Wang W
    Cancer Med; 2021 Jan; 10(2):659-674. PubMed ID: 33314798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative Therapy for Gastric Adenocarcinoma is Protective for Poor Oncologic Outcomes in Patients with Complications After Gastrectomy.
    Vicente D; Ikoma N; Chiang YJ; Fournier K; Tzeng CD; Song S; Mansfield P; Ajani J; Badgwell BD
    Ann Surg Oncol; 2018 Sep; 25(9):2720-2730. PubMed ID: 29987602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of neoadjuvant chemoradiotherapy on perioperative outcomes, tumor pathology, and survival in clinical stage II and III esophageal cancer.
    Markar SR; Bodnar A; Rosales J; Song G; Low DE
    Ann Surg Oncol; 2013 Nov; 20(12):3935-41. PubMed ID: 23892525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mortality and morbidity after resection for adenocarcinoma of the gastroesophageal junction: predictive factors.
    Sauvanet A; Mariette C; Thomas P; Lozac'h P; Segol P; Tiret E; Delpero JR; Collet D; Leborgne J; Pradère B; Bourgeon A; Triboulet JP
    J Am Coll Surg; 2005 Aug; 201(2):253-62. PubMed ID: 16038824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.